Mineralys Therapeutics, Inc. (MLYS) Stock Analysis
Falling Knife setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $23.47: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum.
Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a single asset, lorundrostat, an aldosterone synthase inhibitor for hypertension and related cardiorenal conditions (CKD, OSA). An NDA was submitted in December 2025 with a PDUFA date of December 22, 2026;... Read more
Sell if holding. Engine safety override at $23.47: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 26, MACD bearish. Score 5.1/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 58d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
About Mineralys Therapeutics, Inc.
About Mineralys Therapeutics, Inc.
Mineralys Therapeutics reported net losses of $154.7 million in fiscal year 2025 and $177.8 million in 2024, with an accumulated deficit of $457.2 million at year-end 2025 and no product revenue. The company's sole program, lorundrostat, completed the Phase 3 Launch-HTN trial in March 2025, demonstrating a placebo-adjusted 11.6 mmHg reduction in systolic blood pressure at week 12 in 1,083 randomized patients. An NDA was submitted to the FDA in December 2025, with a PDUFA target action date of December 22, 2026.
Mineralys has no product revenue and funds operations through equity and debt financing. The company in-licensed lorundrostat from Tanabe Pharma Corporation, which discovered the compound and conducted Phase 1 development; milestone and royalty payments to Tanabe are contractually required if the drug is approved. Clinical manufacturing relies on third-party contract manufacturing organizations, and trials were executed through contract research organizations. The pivotal Phase 3 Launch-HTN trial enrolled patients with uncontrolled or resistant hypertension already on two to five antihypertensive medications, targeting a U.S. population of over 30 million uncontrolled hypertensive patients, of whom 10 million have resistant hypertension. The Phase 2 Advance-HTN trial (n=285 randomized) also met its primary endpoint, and the Phase 2 Explore-CKD trial, reported in June 2025, showed statistically significant reductions in both systolic blood pressure and urinary albumin creatinine ratio, potentially broadening the commercial profile.
Show full overview
The FDA accepted the NDA for lorundrostat in December 2025 and set a PDUFA date of December 22, 2026, making that decision the single pivotal event shaping the company's value. The 10-K notes the FDA may require additional clinical data, impose labeling restrictions, or decline approval entirely; the company has not yet arranged commercial-scale manufacturing, established a sales force, or secured third-party payer reimbursement commitments. With a 12-month operating runway disclosed at year-end 2025 and no approved products, Mineralys would likely require additional financing if the approval timeline extends beyond the PDUFA date.
See also: Healthcare · Biotechnology
From Mineralys Therapeutics, Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-15Recent Developments — Mineralys Therapeutics, Inc.
Latest news
- NEWS Reported Sunday, Mineralys Therapeutics Presents Late-Breaking Data At ENDO 2026 Showing Lorundrostat Associated With Si — benzinga Jun 15, 2026 positive
- NEWS Mineralys to Present New Trial Data at ENDO 2026, Proteomic Analysis Selected for Late-Breaking ENDO Poster — benzinga Jun 8, 2026 positive
- NEWS 12 Health Care Stocks Moving In Wednesday's Intraday Session — benzinga Jun 3, 2026 neutral
- NEWS Mineralys Prices $150M Stock Offering Of 5.66M Shares At $26.50/Share, To Use Share Sale Proceeds for Royalty Buyback — benzinga Jun 3, 2026 positive
- NEWS Mineralys Therapeutics To Feature Data From Phase 3 Launch-HTN Trial At ESH 2026 — benzinga May 18, 2026 positive
Generated 2026-06-17T09:02:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinelorundrostat10-K Item 1A: 'We currently only have one product candidate, lorundrostat...Our business presently depends entirely on our ability to successfully obtain regulatory approval'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $23.47: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10 and A.R:R 5.6:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality; Negative price momentum. Chart setup: Death cross, below all MAs, RSI 26, MACD bearish. Prior stop was $21.80. Score 5.1/10, moderate confidence.
Take-profit target: $42.63 (+81.9% upside). Prior stop was $21.80. Stop-loss: $21.80.
Concentration risk — Pipeline: lorundrostat; Quality below floor (1.2 < 4.0).
Mineralys Therapeutics, Inc. trades at a P/E of N/A (forward -11.3). TrendMatrix value score: 9.0/10. Verdict: Sell.
16 analysts cover MLYS with a consensus score of 4.2/5. Average price target: $49.
What does Mineralys Therapeutics, Inc. do?Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a single asset, lorundrostat, an aldosterone...
Mineralys Therapeutics is a clinical-stage biopharmaceutical company with a single asset, lorundrostat, an aldosterone synthase inhibitor for hypertension and related cardiorenal conditions (CKD, OSA). An NDA was submitted in December 2025 with a PDUFA date of December 22, 2026; no approved products and no product revenue to date.